Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.85 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | THRB | P10828 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3523524 | 0.92 | CASP1 (1.00) | CASP1CYP1A2CYP3A4CYP2C9THRB | |
| SCHEMBL11785020 | 0.87 | TP53 (0.73) | CASP1CYP1A2CYP3A4CYP2C9THRB | |
| SCHEMBL11580801 | 0.82 | CYP1A2 (0.65) | CASP1CYP1A2CYP3A4CYP2C9THRB | |
| SCHEMBL21450560 | 0.81 | KDM4E (0.81) | POLBCYP2C19ALDH1A1NPSR1KDM4E | |
| SCHEMBL30884801 | 0.81 | KDM4E (0.81) | POLBCYP2C19ALDH1A1NPSR1KDM4E | |
| SCHEMBL10999598 | 0.77 | KDM4E (0.54) | CASP1CYP1A2CYP3A4CYP2C9THRB | |
| SCHEMBL3523469 | 0.76 | MAPT (0.61) | CASP1CYP1A2CYP3A4CYP2C9THRB | |
| SCHEMBL3523479 | 0.76 | CASP1 (0.61) | CASP1CYP1A2CYP3A4CYP2C9THRB | |
| SCHEMBL6994833 | 0.76 | CASP1 (0.51) | CASP1CYP1A2CYP3A4CYP2C9THRB | |
| SCHEMBL11856611 | 0.75 | MAPT (0.55) | CASP1CYP1A2CYP3A4CYP2C9THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652006-B2 | For therapy and prophylaxis of neuronal loss associated with stroke, global and focal ischemia, CNS trauma, hypoglycemia and surgery, for ameliorating neurodegenerative diseases | EURO-CELTIQUE S.A. (LU) | 2010-01-26 | — | — | US | disclosed |
| US-20040162299-A1 | Substituted quinazolines and analogs and the use thereof | EURO-CELTIQUE, S.A. | 2004-08-19 | — | — | US | disclosed |
| US-6765006-B2 | ANTAGONISTS OF AMINO-3-HYDROXY-5-METHYLISOXAZOLE-4-PROPIONIC ACID (AMPA) IONOTROPIC RECEPTORS; NEURODEGENERATIVE, ALZHEIMER'S, AND HUNTINGTON'S DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; SCHIZOPHRENIA, EXCITATORY AMINO ACID DEFICIENCY | EURO-CELTIQUE S.A. (LU) | 2004-07-20 | — | — | US | disclosed |
| EP-1066039-A4 | SUBSTITUTED QUINAZOLINES AND ANALOGS AND THE USE THEREOF | COCENSYS INC (US) | 2003-02-26 | — | — | EP | disclosed |
| US-20030033089-A1 | Substituted quinazolines and analogs and the use thereof | EURO-CELTIQUE S.A. | 2003-02-13 | — | — | US | disclosed |
| US-6465472-B1 | SUCH AS 1-(2-DIETHYLAMINOETHYL)-6,7-METHYLENEDIOXY-4-(3,4-METHYLENE -DIOXYPHENYL)QUINAZOLIN-2(1H)-ONE; AMPA IONOTROPIC RECEPTOR ANTAGONISTS; ANTICONVULSANTS, COGNITIVE ENHANCERS, PREVENTION OF NEURODEGENERATION | EURO-CELTIQUE S.A. (LU) | 2002-10-15 | — | — | US | disclosed |
| EP-1066039-A1 | SUBSTITUTED QUINAZOLINES AND ANALOGS AND THE USE THEREOF | Cocensys, Inc. (US) | 2001-01-10 | — | — | EP | disclosed |
| WO-1999044612-A1 | SUBSTITUTED QUINAZOLINES AND ANALOGS AND THE USE THEREOF | COCENSYS, INC. (US) | 1999-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162299-A1 | Substituted quinazolines and analogs and the use thereof | CHRNA7, CHRNA2, CHRNA10 | CASP1 4356/4885CYP1A2 2688/4885CYP3A4 2023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.